PERSPECTA

News from every angle

← Back to headlines

Biohaven Shares Rise Following Major Licensing Deal

Biohaven stock gained nearly 7 percent after announcing a significant licensing agreement with SK Biopharmaceuticals to develop and commercialize its pipeline assets. Market analysts maintained positive ratings, citing strong strategic value from the partnership.

PostShare

Sources

Showing 0 of 2 sources

No articles available in your preferred languages.

2 articles available in other languages below.

investing-comDanish1h ago

Biohaven stock holds Buy rating at TD Cowen after SK deal

Read full article →
YahooDanish4h ago

Biohaven shares climb 7% after signing major SK Biopharmaceuticals licensing deal

Read full article →

Coverage Timeline

First report: Yahoo · 26 Aug, 12:28Full coverage: 2 · 3hWindow: 3h
Left-leaningCenterRight-leaning
Yahoo26 Aug, 12:28First to report

Biohaven shares climb 7% after signing major SK Biopharmaceuticals licensing deal

3h later
investing-com26 Aug, 15:48Latest update

Biohaven stock holds Buy rating at TD Cowen after SK deal

Related Stories

New Pacific Metals Secures Contracts and Launches Drilling at Bolivian Site

21m ago

Stanley Druckenmiller takes aim at former colleague Scott Bessent

24m ago

Bayer Construct Files for Self-Initiated Bankruptcy Proceedings

25m ago

nCino and Western Digital Shares Rise on Sector Optimism

29m ago